Izervay

Pharma

Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears

With Xtandi set to lose U.S. patent protection next year, Astellas’ CEO fielded questions this week about his company’s BD strategy ahead of the loss.

Angus Liu Jan 15, 2026 10:42am

Apellis reports 4% sales drop for eye disease med Syfovre

Jan 12, 2026 1:06pm

Astellas Pharma Izervay campaign Babs Costello

Astellas taps Babs Costello to promote Izervay for GA

Oct 23, 2025 2:31pm

China biotech deals, Takeda, LaNova—Fierce Pharma Asia

Jul 18, 2025 9:04am

With sales turnaround, Astellas projects big growth for Izervay

Jul 10, 2025 4:30pm

Astellas looks to continue growth spurt as 'one Astellas': exec

Jun 9, 2025 9:50am